700001 | DC-Cholesterol∙HCl
3ß-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride

Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
DC-Cholesterol∙HCl
3ß-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride
3ß-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride, or DC-Cholesterol∙HCl, is a cationic cholesterol lipid derived from synthetic cholesterol and is widely recognized for its role in gene and drug delivery applications. With its quaternary amine salt at the 3-C position, this lipid enhances the formation of stable liposomes for nucleic acid transport. It forms highly efficient liposomal systems when combined with helper lipids like 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (DOPE).
Application
Researchers widely use DC-Cholesterol∙HCl to prepare cationic liposomes for DNA and siRNA delivery. Studies show that liposomes formed with DC-Chol and DOPE allow efficient gene transfection while displaying lower cytotoxicity compared to other cationic lipids.
Additionally, DC-Cholesterol∙HCl helps with the transportation of low bioavailability therapeutics as a nanocarrier. This includes nucleic acids and small-molecule drugs via liposomal encapsulation.
Another notable characteristic of this cationic lipid is that its liposomes are internalized through macropinocytosis and clathrin-mediated endocytosis to ensure effective cellular uptake and intracellular release of therapeutic agents.
Packaging
Avanti Research™ provides DC-Cholesterol∙HCl in powder (25mg, 200mg, 500mg, and 1g) for various research applications.
Our high-purity products enable consistent results in advanced analyses.
Discover Croda Pharma’s GMP lipids for large-scale production, offering pharmaceutical-grade solutions made to comply with the highest quality and regulatory standards for both clinical and commercial applications.
CAS Registry Number is a Registered Trademark of the American Chemical Society
Lou G, Anderluzzi G, Tandrup Schmidt S, Woods S, Gallorini S, Brazzoli M, Giusti F, Ferlenghi I, Johnson R, Roberts CW, O'Hagan DT, Baudner BC, Perrie Y. Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection. J Control Release. 2020 Jun 30:S0168-3659(20)30362-X. doi: 10.1016/j.jconrel.2020.06.027. Epub ahead of print. PMID: 32619745.
PubMed ID: 32619745Naciute M, Niemi V, Kemp RA, Hook S. Lipid-encapsulated oral therapeutic peptide vaccines reduce tumour growth in an orthotopic mouse model of colorectal cancer. Eur J Pharm Biopharm. 2020 Jul;152:183-192. doi: 10.1016/j.ejpb.2020.04.020. Epub 2020 May 4. PMID: 32380167.
PubMed ID: 32380167Yang K, Mesquita B, Horvatovich P, Salvati A. Tuning liposome composition to modulate corona formation in human serum and cellular uptake. Acta Biomater. 2020 Apr 1;106:314-327. doi: 10.1016/j.actbio.2020.02.018. Epub 2020 Feb 17. PMID: 32081780.
PubMed ID: 32081780Lee J, Cho YJ, Lee JW, Ahn HJ. KSP siRNA/paclitaxel-loaded PEGylated cationic liposomes for overcoming resistance to KSP inhibitors: Synergistic antitumor effects in drug-resistant ovarian cancer. J Control Release. 2020 Feb 6;321:184-197. doi: 10.1016/j.jconrel.2020.02.013. Epub ahead of print. PMID: 32035195.
PubMed ID: 32035195Palchetti S, Digiacomo L, Giulimondi F, Pozzi D, Peruzzi G, Ferri G, Amenitsch H, Cardarelli F, Mahmoudi M, Caracciolo G. A mechanistic explanation of the inhibitory role of the protein corona on liposomal gene expression. Biochim Biophys Acta Biomembr. 2020 Mar 1;1862(3):183159. doi: 10.1016/j.bbamem.2019.183159. Epub 2019 Dec 16. PMID: 31857070.
PubMed ID: 31857070Fabio Vischio, Elisabetta Fanizza, Vito De Bellis, Teresa Sibillano, Chiara Ingrosso, Cinzia Giannini, Valentino Laquintana, Nunzio Denora, Angela Agostiano, Marinella Striccoli, M. Lucia Curri, and Nicoletta Depalo. Near-Infrared Absorbing Solid Lipid Nanoparticles Encapsulating Plasmonic Copper Sulfide Nanocrystals. J. Phys. Chem. C 2019, 123, 23205−23213
Cai J, Huang S, Yi Y, Bao S. Ultrasound microbubble-mediated CRISPR/Cas9 knockout of C-erbB-2 in HEC-1A cells. J Int Med Res. 2019 May;47(5):2199-2206. doi: 10.1177/0300060519840890. Epub 2019 Apr 14.
PubMed ID: 30983484Kommineni N, Mahira S, Domb AJ, Khan W. Cabazitaxel-Loaded Nanocarriers for Cancer Therapy with Reduced Side Effects. Pharmaceutics. 2019 Mar 25;11(3). pii: E141. doi: 10.3390/pharmaceutics11030141.
PubMed ID: 30934535Byeon JC, Lee SE, Kim TH, Ahn JB, Kim DH, Choi JS, Park JS. Design of novel proliposome formulation for antioxidant peptide, glutathione with enhanced oral bioavailability and stability. Drug Deliv. 2019 Dec;26(1):216-225. doi: 10.1080/10717544.2018.1551441.
PubMed ID: 30843439Nassir AM, Ibrahim IAA, Md S, Waris M, Tanuja, Ain MR, Ahmad I, Shahzad N. Surface functionalized folate targeted oleuropein nano-liposomes for prostate tumor targeting: Invitro and invivo activity. Life Sci. 2019 Mar 1;220:136-146. doi: 10.1016/j.lfs.2019.01.053. Epub 2019 Jan 31.
PubMed ID: 30710640Loria R, Giliberti C, Bedini A, Palomba R, Caracciolo G, Ceci P, Falvo E, Marconi R, Falcioni R, Bossi G, Strigari L. Very low intensity ultrasounds as a new strategy to improve selective delivery of nanoparticles-complexes in cancer cells. J Exp Clin Cancer Res. 2019 Jan 3;38(1):1. doi: 10.1186/s13046-018-1018-6.
PubMed ID: 30606223Colonna, C., Conti, B., Genta, I., Alpar, O.H. (2008) Non-viral dried powders for respiratory gene delivery prepared by cationic and chitosan loaded liposomes. Int J Pharm. 364:108-18. [PubMed]
PubMed ID: 18775770Maitani, Y., Aso, Y., Yamada, A., Yoshioka, S. (2008) Effect of sugars on storage stability of lyophilized liposome/DNA complexes with high transfection efficiency. Int J Pharm. 356:69-75. [PubMed]
PubMed ID: 18249511Maitani, Y., Igarashi, S., Sato, M., Hattori, Y. (2007) Cationic liposome (DC-Chol/DOPE=1:2) and a modified ethanol injection method to prepare liposomes, increased gene expression. Int J Pharm. 342:33-9. [PubMed]
PubMed ID: 17566677Preferential Adsorption of l-Histidine onto DOPC/Sphingomyelin/3β-[N-(N′,N′-dimethylaminoethane)carbamoyl]cholesterol Liposomes in the Presence of Chiral Organic Acids Keishi Suga, Atsushi Tauchi, Takaaki Ishigami, Yukihiro Okamoto, and Hiroshi Umakoshi* Langmuir, Article ASAP [PubMed]
PubMed ID: 28272888- Certificate of Analysis (Lot No. 700001P-1G-A-021 and 5093PQA021)
- Certificate of Analysis (Lot No. 700001P-200MG-A-021 and 5093PNA021)
- Certificate of Analysis (Lot No. 700001P-25MG-A-021 and 5093PJA021)
- Certificate of Analysis (Lot No. 700001P-500MG-A-021 and 5093PPA021)
- Certificate of Analysis (Lot No. 700001P-1G-B-021 and 5093PQB021)
- Certificate of Analysis (Lot No. 700001P-200MG-B-021 and 5093PNB021)
- Certificate of Analysis (Lot No. 700001P-25MG-B-021 and 5093PJB021)
- Certificate of Analysis (Lot No. 700001P-500MG-B-021 and 5093PPB021)
- Certificate of Analysis (Lot No. 700001P-25MG-C-021 and 5093PJC021)
- Certificate of Analysis (Lot No. 700001P-200MG-C-021 and 5093PNC021)
- Certificate of Analysis (Lot No. 700001P-500MG-A-022 and 5093PPA022)
- Certificate of Analysis (Lot No. 700001P-1G-A-022 and 5093PQA022)
- Certificate of Analysis (Lot No. 700001P-200MG-A-022 and 5093PNA022)
- Certificate of Analysis (Lot No. 700001P-25MG-A-022 and 5093PJA022)
- Certificate of Analysis (Lot No. 700001P-1G-B-022 and 5093PQB022)
- Certificate of Analysis (Lot No. 700001P-25MG-B-022 and 5093PJB022)
- Certificate of Analysis (Lot No. 700001P-1G-C-022 and 5093PQC022)
- Certificate of Analysis (Lot No. 700001P-500MG-B-022 and 5093PPB022)
- Certificate of Analysis (Lot No. 700001P-25MG-C-022 and 5093PJC022)
- Certificate of Analysis (Lot No. 700001P-1G-D-022 and 5093PQD022)
- Certificate of Analysis (Lot No. 700001P-200MG-B-022 and 5093PNB022)
- Certificate of Analysis (Lot No. 700001P-1G-A-023 and 5093PQA023)
- Certificate of Analysis (Lot No. 700001P-1G-B-023 and 5093PQB023)
- Certificate of Analysis (Lot No. 700001P-25MG-A-023 and 5093PJA023)
- Certificate of Analysis (Lot No. 700001P-500MG-A-023 and 5093PPA023)
- Certificate of Analysis (Lot No. 700001P-1G-C-023 and 5093PQC023)
- Certificate of Analysis (Lot No. 700001P-200MG-A-024 and 5093PNA024)
- Certificate of Analysis (Lot No. 700001P-25MG-B-023 and 5093PJB023)
- Certificate of Analysis (Lot No. 700001P-25MG-B-024 and 5093PJB024)
- Certificate of Analysis (Lot No. 700001P-25MG-C-024 and 5093PJC024)
- Certificate of Analysis (Lot No. 700001P-1G-A-025 and 5093PQA025)
- Certificate of Analysis (Lot No. 700001P-200MG-C-024 and 5093PNC024)
- Certificate of Analysis (Lot No. 700001P-200MG-D-024 and 5093PND024)
- Certificate of Analysis (Lot No. 700001P-25MG-D-024 and 5093PJD024)
- Certificate of Analysis (Lot No. 700001P-CONF-B-025 and 5093PWB025)
- Certificate of Analysis (Lot No. 700001P-500MG-B-024 and 5093PPB024)
- Certificate of Analysis (Lot No. 700001P-200MG-E-024 and 5093PNE024)
- Certificate of Analysis (Lot No. 700001P-25MG-E-024 and 5093PJE024)
- Certificate of Analysis (Lot No. 700001P-200MG-F-024 and 5093PNF024)
- Certificate of Analysis (Lot No. 700001P-25MG-A-025 and 5093PJA025)
- Certificate of Analysis (Lot No. 700001P-500MG-A-025 and 5093PPA025)
- Certificate of Analysis (Lot No. 700001P-200MG-A-026 and 5093PNA026)